bitBiome, Inc. announces that it has resolved the following change to its Chairman of the Board and CEO, effective on March 30, 2021.
1. Purpose of the Change
Since its inception in November 2018, bitBiome, Inc. has been conducting collaborative research and contract analysis service with various institutions through single-cell genome analysis of microorganisms.
With this change, bitBiome established the optimal organization structure from both the management strategy and the business development, and will accelerate the provision of value to society and industry through our proprietary microbial single-cell genome analysis platform.
2. Details of the Change
3. Biography of the New Appointee
CEO and Chairman of the Board
Kimihiko Sato obtained his master’s degree in molecular biology at the University of Tokyo. He started his career at Mitsui Sumitomo Insurance Company, in the product development department working on actuarial science.
He then worked as a management consultant at Boston Consulting Group for seven years, specific to the healthcare industry. Managing a team as a Project Leader, he developed and implemented a broad range of strategies such as mid/long-term corporate growth, new product launch, sales, and manufacturing for global and Japanese pharmaceutical companies.
He joined bitBiome Inc. in February 2020 and took on his current role in March 2021.